| 1 |
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Huib A.M. Kerstjens, Michael Engel, Ronald Dahl et al. · New England Journal of Medicine
Open access |
2 Sep 2012 |
668 |
| 2 |
A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study
John Wendall Goodwin, John Crowley, Harmon J. Eyre et al. · Journal of Neuro-Oncology
|
1993 |
179 |
| 3 |
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
Carol A Aghajanian, Virginia L. Filiaci, Don Steven Dizon et al. · Gynecologic Oncology
Open access |
24 May 2018 |
148 |
| 4 |
GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients
Jay W. Carlson, James T. Kauderer, Alan David Hutson et al. · Gynecologic Oncology
Open access |
16 Dec 2019 |
128 |
| 5 |
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
Bradley J. Monk, James T. Kauderer, Katherine Marie Moxley et al. · Gynecologic Oncology
Open access |
8 Oct 2018 |
125 |
| 6 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
Agustin A. García, Michael W. Sill, Heather A. Lankes et al. · Gynecologic Oncology
Open access |
28 Oct 2011 |
122 |
| 7 |
A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)
Sara Hughes Javid, Joseph M. Unger, Julie R. Gralow et al. · The Oncologist
Open access |
20 Jun 2012 |
110 |
| 8 |
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
Daniel Peter Petrylak, Catherine M. Tangen, Peter J. Van Veldhuizen et al. · British Journal of Urology
|
2 Nov 2009 |
106 |
| 9 |
Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897
Peter Ganz, Michael A. Hussey, Carol M. Moinpour et al. · Journal of Clinical Oncology
Open access |
29 Jan 2008 |
85 |
| 10 |
Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study
Allan L. Covens, Virginia L. Filiaci, Deborah J. Gersell et al. · Gynecologic Oncology
|
14 Nov 2010 |
77 |
| 11 |
A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes
Sandhya Pruthi, Rui Qin, Shelby A. Terstreip et al. · Menopause The Journal of The North American Menopause Society
Open access |
4 Oct 2011 |
76 |
| 12 |
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study
Robert P. Whitehead, Sheryl McCoy, Saul E. Rivkin et al. · Investigational New Drugs
|
11 May 2006 |
71 |
| 13 |
Letting Go? Sharing Historical Authority in a User-Generated World
Alex T. Primm · The Oral History Review
|
2012 |
70 |
| 14 |
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
David Samuel Alberts, John A. Blessing, Lisa Michelle Landrum et al. · Gynecologic Oncology
Open access |
14 Sep 2012 |
70 |
| 15 |
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function
Jeanne Carter, Helen Q. Huang, Jane M. Armer et al. · Gynecologic Oncology
Open access |
24 Oct 2020 |
69 |
| 16 |
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
David Scott Miller, John A. Blessing, Diane C. Bodurka et al. · Gynecologic Oncology
|
6 May 2008 |
66 |
| 17 |
Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
John Wendall Goodwin, Stephanie Green, Carol M. Moinpour et al. · Journal of Clinical Oncology
Open access |
29 Mar 2008 |
65 |
| 18 |
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE)
Jeanne Carter, Helen Q. Huang, Jane M. Armer et al. · Gynecologic Oncology
Open access |
Nov 2019 |
54 |
| 19 |
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109
Peter J. Van Veldhuizen, James R. Faulkner, Primo N. Lara et al. · Cancer Chemotherapy and Pharmacology
|
24 Mar 2005 |
38 |
| 20 |
Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers
Sandra A. Russo et al. · Gynecologic Oncology
Open access |
4 Nov 2020 |
34 |
| 21 |
Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A southwest oncology group pilot study
Carol J. Fabian, Shankar P. G. Giri, Norman C. Estes et al. · International Journal of Radiation Oncology*Biology*Physics
|
May 1995 |
30 |
| 22 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
Robert Louis Coleman, James Moon, Anil K. Sood et al. · European Journal of Cancer
Open access |
4 Apr 2014 |
30 |
| 23 |
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
Kenneth J. Pienta, Emily I. Fisher, Mario A. Eisenberger et al. · The Prostate
|
2001 |
30 |
| 24 |
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
William P. Tew, Michael W. Sill, Joan L. Walker et al. · Gynecologic Oncology
Open access |
31 Aug 2018 |
29 |
| 25 |
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Ursula A. Matulonis, Michael W. Sill, Vicky Makker et al. · Gynecologic Oncology
Open access |
23 Dec 2018 |
28 |
| 26 |
A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
Laurence Elias, Brent A. Blumenstein, Julie Ann Kish et al. · Cancer
|
Sep 1996 |
26 |
| 27 |
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial
John H. Farley, William E. Brady, David M. O’Malley et al. · Gynecologic Oncology
Open access |
14 Oct 2022 |
25 |
| 28 |
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Charles A. Kunos, Tomas Radivoyevitch, Fadi W. Abdul‐Karim et al. · Journal of Translational Medicine
Open access |
27 Apr 2012 |
25 |
| 29 |
Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)
Paul Joseph Hesketh, Kari Chansky, Derick H. Lau et al. · Journal of Thoracic Oncology
Open access |
Jul 2006 |
24 |
| 30 |
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
Russell J. Schilder, Michael W. Sill, Heather A. Lankes et al. · Gynecologic Oncology
Open access |
13 Jan 2013 |
24 |
| 31 |
Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study
Geoffrey R. Weiss, Stephanie Green, David S. Alberts et al. · European Journal of Cancer and Clinical Oncology
|
1991 |
24 |
| 32 |
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Aine Clements et al. · Gynecologic Oncology
Open access |
23 Jan 2025 |
23 |
| 33 |
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study
Amina Ismail Ahmed, Wei Deng, William P. Tew et al. · Gynecologic Oncology
Open access |
25 May 2018 |
21 |
| 34 |
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
John K. Chan, Wei Deng, Robert V. Higgins et al. · Gynecologic Oncology
Open access |
18 Jul 2017 |
21 |
| 35 |
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study
Stephen K. Williamson, John J. Crowley, Robert B. Livingston et al. · Investigational New Drugs
|
Mar 1995 |
20 |
| 36 |
Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study
Arlene Odelia Siefker-Radtke, Matthew T. Campbell, Mark F. Munsell et al. · Urology
Open access |
23 Dec 2015 |
20 |
| 37 |
Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A southwest oncology group study
Georgiana Kehr Ellis, Robert B. Livingston, John Crowley et al. · Cancer
|
15 Jun 1991 |
19 |
| 38 |
Genome-wide host methylation profiling of anal and cervical carcinoma
Erin M. Siegel, Abidemi O. Ajidahun, Anders Berglund et al. · PLoS ONE
Open access |
9 Dec 2021 |
18 |
| 39 |
Songbird nest success is positively related to restoration of pine–oak savanna and woodland in the Ozark Highlands, Missouri, USA
Melissa C. Roach, Frank R. III Thompson, Todd Jones‐Farrand · Ornithological Applications
Open access |
6 Jun 2018 |
18 |
| 40 |
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
Jubilee Brown, Austin Miller, Laura L. Holman et al. · Gynecologic Oncology
Open access |
12 Sep 2024 |
17 |
| 41 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Bradley J. Monk, Michael W. Sill, Parviz Hanjani et al. · Gynecologic Oncology
|
8 Dec 2010 |
17 |
| 42 |
Effect of Transdermal Methylphenidate Wear Times on Sleep in Children With Attention Deficit Hyperactivity Disorder
Arie Ashkenasi · Pediatric Neurology
|
22 Nov 2011 |
17 |
| 43 |
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811
Corinne Doll, Jennifer Moughan, Alexander C. Klimowicz et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
23 Nov 2016 |
16 |
| 44 |
Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies
Sarah A. Taylor, John Crowley, Jennette Townsend et al. · Journal of Neuro-Oncology
|
Feb 1993 |
15 |
| 45 |
Dacarbazine and Outpatient Interleukin-2 in Treatment of Metastatic Malignant Melanoma: Phase II Southwest Oncology Group Trial
Lawrence E. Flaherty, Pengfei Liu, William S. Fletcher et al. · JNCI Journal of the National Cancer Institute
|
3 Jun 1992 |
14 |
| 46 |
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Leonard Friedlander, James Java et al. · Gynecologic Oncology
Open access |
11 Jul 2022 |
12 |
| 47 |
Concurrent Cisplatin, Prolonged Oral Etoposide, and Vincristine plus Chest and Brain Irradiation for Limited Small Cell Lung Cancer: A Phase II Study of the Southwest Oncology Group (SWOG-9229)
Charles R. Thomas, Dorothy J. Giroux, Keith J. Stelzer et al. · International Journal of Radiation Oncology*Biology*Physics
|
15 Mar 1998 |
11 |
| 48 |
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial
Maurie M. Markman, Tracy R. Glass, Harriet Olivia Smith et al. · Gynecologic Oncology
|
Mar 2003 |
11 |
| 49 |
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Charles E. Geyer, Hanna Bandos, Priya Rastogi et al. · Breast Cancer Research and Treatment
Open access |
Mar 2022 |
10 |
| 50 |
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas
Mark M. Zalupski, Jacqueline Benedetti, Stanley P. Balcerzak et al. · Investigational New Drugs
|
Dec 1993 |
10 |